Pfizer Q2 Results: Adj. EPS beats estimates, sales rise 2.3%

1 min read     Updated on 04 Aug 2026, 05:32 PM
scanx
Reviewed by
Anirudha BScanX News Team
AI Summary

Pfizer’s Q2 results show adjusted EPS of $0.77, beating the $0.69 estimate by 11.59%. Sales grew 2.27% YoY to $15.034 billion, surpassing the $14.412 billion forecast. Although EPS declined slightly from $0.78 in the prior year, the strong beat highlights robust margin performance.

powered bylight_fuzz_icon
47390556

*this image is generated using AI for illustrative purposes only.

Pfizer delivered stronger-than-expected financial performance in its second quarter, reporting adjusted earnings per share (EPS) of $0.77 against an analyst consensus estimate of $0.69. The company’s quarterly sales reached $15.034 billion, exceeding the projected $14.412 billion and marking a modest growth trajectory compared to the prior year.

The results indicate that while top-line revenue growth remains moderate at 2.27% year-over-year, profitability metrics outperformed market expectations. The adjusted EPS beat of 11.59% suggests effective cost management or margin expansion despite the slight decline in absolute earnings compared to the previous year’s figure of $0.78 per share.

Financial Performance Overview

The key financial indicators for the quarter highlight a divergence between revenue growth and earnings power. While sales increased from $14.7 billion in the same period last year to $15.034 billion, the adjusted EPS decreased slightly by 1.28% from $0.78 to $0.77 on a year-over-year basis. However, the significant beat against analyst estimates underscores the company’s ability to generate value beyond initial market projections.

Metric Reported Value Estimate Beat/Miss YoY Change
Adjusted EPS $0.77 $0.69 +11.59% -1.28%
Quarterly Sales $15.034 billion $14.412 billion +4.31% +2.27%

What the Numbers Show

The analytical observation from these figures is that Pfizer’s operational efficiency appears to be driving earnings quality more than volume growth. With sales rising only 2.27% year-over-year, the substantial 11.59% beat on EPS estimates implies that non-operational factors or disciplined expense control played a critical role in the quarter’s outcome. Investors should note that while the absolute EPS dipped slightly from last year’s $0.78, it significantly exceeded current market expectations, signaling resilience in the company’s core business model despite modest top-line expansion.

Historical Stock Returns for Pfizer

1 Day5 Days1 Month6 Months1 Year5 Years
-0.06%+1.11%+7.47%+2.38%-2.84%-16.60%

How sustainable is Pfizer's current cost management strategy in driving margin expansion as top-line growth remains modest?

Which specific product segments or therapeutic areas are expected to drive the next phase of revenue acceleration beyond the current 2.27% YoY growth?

Will the significant EPS beat lead to an upward revision of full-year guidance or analyst consensus estimates for Pfizer?

Pfizer shareholders approve ₹75 dividend, reappoint P. Rengan

2 min read     Updated on 30 Jul 2026, 09:18 AM
scanx
Reviewed by
Jubin VScanX News Team
AI Summary

Pfizer Limited's 75th AGM concluded with unanimous shareholder support for key resolutions, including a ₹75 per share dividend and the reappointment of P. Rengan. The virtual meeting saw high participation from promoters and institutional investors, with all proposals passing under SEBI regulations.

powered bylight_fuzz_icon
46796278

*this image is generated using AI for illustrative purposes only.

Pfizer Limited shareholders have overwhelmingly approved a final dividend of ₹75 per equity share for FY26 and reappointed P. Rengan as a director during its 75th Annual General Meeting (AGM). The virtual meeting, held on July 28, 2026, saw all four resolutions pass with more than 99% support from voting members, underscoring strong stakeholder confidence in the company’s governance and financial distribution plans.

The e-voting results were filed with the BSE and NSE pursuant to Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting was conducted via Video Conferencing and Other Audio-Visual Means (VC/OVAM) in compliance with Ministry of Corporate Affairs (MCA) and SEBI circulars. Pradip Shah, Chairman and Non-Independent Non-Executive Director, chaired the session from Mumbai, while Ms. Meenakshi Nevatia, Managing Director, presented the company’s performance overview.

Voting Results Breakdown

A total of 391 members cast votes across remote e-voting and live electronic polling, representing approximately 81.96% of the outstanding shares. The promoter group, holding 63.92% of the capital, voted in favor of all resolutions without any dissent. Public institutional investors also showed near-unanimous support, while retail participation remained low but largely positive.

Resolution Votes In Favor Votes Against Support %
Adoption of Financial Statements 3,74,95,762 83 99.99%
Declaration of ₹75 Dividend 3,74,95,769 75 99.99%
Re-appointment of P. Rengan 3,74,03,760 85,085 99.77%
Ratification of Cost Auditor Fees 3,74,88,732 113 99.99%

The dividend declaration represents a significant return to shareholders for the financial year ended March 31, 2026. The re-appointment of Mr. P. Rengan (DIN: 10362899), who retired by rotation under Section 152(6) of the Companies Act, 2013, ensures continuity in board oversight of plant operations. Additionally, shareholders ratified the remuneration payable to M/s. Kishore Bhatia & Associates, Cost Accountants, for the financial year ending March 31, 2027.

Governance and Compliance

CS Nrupang B. Dholakia, Managing Partner of Dholakia & Associates LLP, served as the independent scrutinizer for the voting process. The remote e-voting window ran from July 24 to July 27, 2026, followed by a 15-minute live e-voting period during the AGM. Statutory Auditors, Secretarial Auditor, and Cost Auditor attended via video conference; their reports contained no qualifications or adverse remarks. Physical copies of the Annual Report were dispatched only upon request, aligning with digital-first communication policies.

Historical Stock Returns for Pfizer

1 Day5 Days1 Month6 Months1 Year5 Years
-0.06%+1.11%+7.47%+2.38%-2.84%-16.60%

How does the ₹75 dividend per share compare to Pfizer Limited's payout ratios in previous fiscal years, and what does this signal about future capital allocation strategies?

Given the low retail participation despite high institutional support, are there specific initiatives planned to improve engagement with small shareholders in upcoming meetings?

What strategic initiatives is P. Rengan expected to lead regarding plant operations and cost efficiency following his re-appointment as director?

More News on Pfizer

1 Year Returns:-2.84%